Molecularly Targeted Therapy in Breast Cancer: The New Generation

Author(s): Zeina A. Nahleh

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 3 , Issue 2 , 2008

Become EABM
Become Reviewer
Call for Editor


Breast cancer management has become increasingly complex, requiring the integration of data not only from the patients history and imaging modalities but also from specific tumor biomarkers and gene expression. Targeted and biologic therapies in breast cancer continue to evolve rapidly. The field of molecular targeted therapy has emerged. Its ultimate goal is to personalize and simplify treatment as well as minimize toxicity. This review aims at highlighting the current state-of-the-art in novel molecular targeted therapies for breast cancer based on multi-targeted small molecule tyrosine kinase inhibitors (TKI). The first two agents in this group entering clinic, Lapatinib (GW572016; Tykerb ®) and SUNITINIB (SU11248; Sutent®) are discussed. This review article also includes relevant patents.

Keywords: Multitargeted, small molecule, tyrosine kinase inhibitors, breast cancer

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [100 - 104]
Pages: 5
DOI: 10.2174/157489208784638794
Price: $65

Article Metrics

PDF: 5